ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
48 announcements with these filters
Evonile Pharma's board approved a partly paid rights issue of up to Rs 900 Crore. A committee will set the issue price, record date and entitlement.
Evonile Pharma's Rights Issue Committee fixed November 11, 2026 as record date for a partly paid rights issue of 1,02,87,832 shares at Rs.860 each. Issue size is Rs.8,847.54 Million, with issue opening November 19, 2026.
Q2 FY27 revenue ₹56.1 cr (-38% YoY) and PAT loss ₹77.5 cr, including ₹68 cr exceptional items. H1 revenue ₹159.9 cr (-10%). Transitioning to an independent branded pharma model; Minipress XL acquired.
Evonile Pharma reported Q2 FY27 revenue of ₹56.1 crore and an EBITDA loss of ₹31.8 crore. H1 FY27 profit after tax was a loss of ₹45.3 crore.
Q2 FY27 revenue fell 38% YoY to ₹56.1 cr, with a ₹77.5 cr net loss including ₹68 cr exceptional items. Transition from single-customer model to independent distribution continues.
Evonile Pharma posted a ₹775.4 million quarterly loss for September 2026 versus profit a quarter earlier. Exceptional items of ₹682.6 million drove the half-year pre-tax loss.
Evonile Pharma will hold a board meeting on November 4, 2026 to approve the rights issue letter of offer. BSE granted in-principle approval for the rights issue.
Evonile Pharma (formerly Novartis India) appointed Mr. Gagan Sharma as President – Specialty Business and Senior Management Personnel effective October 26, 2026. The filing is a Regulation 30 senior management appointment intimation.
Novartis India Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations. This is a routine periodic disclosure.
Evonile Pharma (fka Novartis India) issued a postal ballot notice for shareholder votes on ESOP 2026 grant to the MD & CEO and creation of charge on assets. E-voting runs 14 Oct–12 Nov 2026.
Evonile Pharma Limited approved a rights issue to raise up to ₹900 Crore. The company also formed a committee to manage the issuance terms.
Evonile Pharma Limited has received credit ratings from CARE Ratings Limited for its bank facilities. The company disclosed the ratings as part of its regulatory filings.
Novartis India Limited has changed its corporate name to Evonile Pharma Limited, effective October 01, 2026, following approval from the Ministry of Corporate Affairs.
Novartis India Ltd will hold a board meeting on November 03, 2026, to consider its quarterly and half-year financial results. The trading window closes on October 01, 2026.
Novartis India issued a corrigendum to its 78th AGM notice. This correction clarifies ESOP 2026 scheme details and the company's nature of industry.
Novartis India transition to ChrysCapital ownership (70.68%), pivoting from a partner-led model to a direct, in-house commercial platform focusing on chronic therapies like cardiology and ophthalmology.
Novartis India Limited (NIL) shifts to a direct-to-market model under new ownership by ChrysCapital, acquiring the 'Minipress' brand for ₹1,250 Cr and in-licensing an ophthalmic portfolio.
Novartis India dispatched physical letters with the FY25-26 Annual Report web-link to non-email shareholders per Reg 36(1)(b). This is a routine compliance communication with no financial or business impact.
Novartis India signed an exclusive distribution deal with Novartis Healthcare for its retina portfolio in India. Upfront consideration of INR 10 Crore expands NIL's ophthalmology presence.
Novartis India acquired trademarks 'Minipress' and 'Minipres' from Pfizer for ₹1,250.001 Crore. The IP acquisition strengthens its hypertension and BPH portfolio in India.
Novartis India acquired Minipress/Minipres trademarks and related IP from Pfizer for ₹1,250 Crore. The board approved and the asset purchase agreement was executed on September 7, 2026.
Novartis India Limited submits its Annual Report for FY 2025-26 and notice for the 78th Annual General Meeting scheduled on September 24, 2026.
Novartis India's board approved adopting a new Memorandum of Association and a proposal to change the company's name, both subject to shareholder approval at the AGM.
This is the quarterly shareholding pattern filing for Novartis India Ltd as per SEBI regulations. No significant corporate event is disclosed in this submission.
Novartis India terminated its 2022 distribution agreement with Dr. Reddy's Laboratories, effective September 30, 2026. The company will now re-acquire exclusive product distribution and marketing rights.
Novartis India's Board approved the termination of a distribution agreement with Dr. Reddy's, alongside adopting new Articles, an ESOP 2026 plan, and the 78th AGM notice.
Novartis India executed a royalty-free license deed for the 'Tegrital' trademark. This agreement allows the company to manufacture and market the Tegrital pharmaceutical product range.
Novartis India announced a board reconstitution, appointing six new directors and accepting the resignations of seven directors and the company's Chief Financial Officer.
Novartis India Limited reconstituted its Audit, Nomination and Remuneration, and Corporate Social Responsibility committees following director appointments and resignations during its 246th Board Meeting.
Novartis AG sold its entire 70.68% stake (1,74,50,680 shares) in Novartis India Limited. The seller is reclassifying from promoter to public category following this divestment.